Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...
Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto-injector ...
On first impression, the Dacia Spring makes a tempting case for itself, with its low price making it easier to overlook the flaws that often come with a car built down to a budget. However, delve a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results